FDA public Meeting Statement on Abuse Deterrent Opioid Formulations 10-30-14
GHLF Idaho Board of Pharmacy Proposed Rule Testimony 10-22-14
GHLF Idaho Board of Pharmacy Testimony 8-6-14
GHLF Indiana Health Finance Commission Biosimilars Testimony
GHLF Pennsylvania House Biosimilars Testimony